Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
about
Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemiaAdministrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemiaAlternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Variation in medicaid coverage for hematopoietic cell transplantation.Management of older or unfit patients with acute myeloid leukemiaHow we treat chronic graft-versus-host disease.Blood and marrow transplant clinical trials network state of the Science Symposium 2014The treatment of elderly patients with acute myeloid leukemia.In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 YearsSurvival for older patients with acute myeloid leukemia: a population-based studyOutcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.Emerging immunotherapies in older adults with acute myeloid leukemia.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.Acute myeloid leukemia and myelodysplastic syndromes in older adults.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Targeting FLT3 to treat leukemia.Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia.Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.Toward a better management of older patients with acute myeloid leukemia.Provision of long-term monitoring and late effects services following adult allogeneic haematopoietic stem cell transplant: a survey of UK NHS-based programmes.The impact of physical activity and sex differences on intraindividual variability in inhibitory performance in older adults.
P2860
Q26744283-DB7F344A-567E-4597-9960-6230CC1274F3Q31096463-7BA6B95E-CAE2-48AA-8E3D-3FF525E93E53Q33680186-2A99BDFB-1DF7-4B6E-B735-E806AA8690E8Q33859061-5EDBE935-9804-4A88-BA5A-724E8A2E5D01Q34054278-BEA9BA80-4473-4825-B2FE-02EF7CC69653Q34893307-0FC5250B-A23A-47A6-946F-8C0C97168D20Q35004923-50F33FC9-8B8D-4953-8175-3E0B4DEE09B6Q35591760-DAEE8233-8053-4ACE-9AA6-394693AD035CQ35673578-FE46FB1F-07DA-4B8B-B306-116F3C7061ABQ35772737-5B234E00-1E71-42CF-854A-DED1FD8471C0Q35863989-9B40B7D1-A99D-4D06-8FD9-A2032D1E6C99Q36623075-09C16277-E8C9-4B52-88F5-56DA580C32C3Q36662052-ADBD957A-B35B-4357-82F6-1A440D3F076FQ36723291-90E33DEA-074C-4398-AD28-FD230C15E5B7Q36753274-1713936B-5413-46A8-B14A-FEF9E0821B45Q37605585-C675130D-7E4F-481F-A086-6D17EC1A5F5DQ38075407-FAC38843-3F7C-4A67-8722-800E716F1488Q38104287-5DC8B86A-CA0B-4CE5-ACD1-9EBA2D5973C9Q38161965-4661F3B1-389B-494B-B573-115CBA0A4FB2Q38199056-8EBC1206-18DD-4067-9E91-0AEC4FD94B21Q38208953-53BF92AC-CFFB-4B97-9A63-4E143C133C61Q38232465-ED14485E-8E97-4A57-8559-0D1BD7C6ACABQ38234863-E7085645-B6F8-46CD-9F09-E062ADE10806Q38248427-23A1D481-1B06-46EE-866B-9C2280CA2F9AQ38251339-23840429-E2B7-44AD-B699-EC4106CB9A63Q38488058-8AE2D99B-9232-4C00-AAEE-431D6197C6C5Q38601723-49E5B63E-545B-4298-B6AB-09B0D9BD7DCDQ38926882-1858E444-795C-4E5C-8984-F39E07FE8FF6Q38952815-ECD8E430-B944-4F65-8930-41B8880967C1Q39282540-831478AE-8696-4D9C-922F-C9CF00C7B250Q40216218-C0CC191E-C701-4366-9F1D-19CF703D2970Q43086102-AA8EF07D-2776-4514-8030-D2B5BABDE387Q46211544-AA8BB6F0-E55B-4525-8125-6A3F30670BBCQ47146837-1072D39C-B7D2-4A14-95B0-F9B718C91B30Q47770899-1F7BD443-635C-4140-9554-93B5840FC508Q48133412-68C8F8BB-7378-422C-BFAB-A10FF6B850A7Q48568919-C37F5CE7-1BC9-4036-A289-97B0E8B295A2Q48660711-DFAF5E5C-B9EB-4868-A4E8-0C854C9221ADQ50226487-75C9D83D-3C9A-4E6E-A583-CE9D4CACF2E1
P2860
Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Comparison of reduced-intensit ...... s leukemia in first remission.
@ast
Comparison of reduced-intensit ...... s leukemia in first remission.
@en
Comparison of reduced-intensit ...... s leukemia in first remission.
@nl
type
label
Comparison of reduced-intensit ...... s leukemia in first remission.
@ast
Comparison of reduced-intensit ...... s leukemia in first remission.
@en
Comparison of reduced-intensit ...... s leukemia in first remission.
@nl
prefLabel
Comparison of reduced-intensit ...... s leukemia in first remission.
@ast
Comparison of reduced-intensit ...... s leukemia in first remission.
@en
Comparison of reduced-intensit ...... s leukemia in first remission.
@nl
P2093
P2860
P50
P921
P1476
Comparison of reduced-intensit ...... s leukemia in first remission.
@en
P2093
Acute Leukemia Committee of th ...... nd Cancer and Leukemia Group B
Corey S Cutler
Daniel J Weisdorf
David A Rizzieri
David I Marks
Donald W Bunjes
Edward Copelan
John DiPersio
Luis Isola
Maria R Baer
P2860
P304
P356
10.1016/J.BBMT.2011.06.005
P577
2011-06-21T00:00:00Z